SFA Therapeutics is a clinical-stage biopharmaceutical company developing first-in-class, orally delivered small-molecule Treg modulators that restore immune homeostasis. Built on research into natural immune regulators originating in the gut, its targeted biosynthesis platform creates disease-specific drugs for autoimmune and inflammatory conditions, select cancers, infectious and liver diseases, offering predictable outcomes, superior safety, and scalable manufacturing.